期刊
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
卷 37, 期 3, 页码 415-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2011.07.003
关键词
Glucocorticoids; Osteoporosis; Fractures; Bisphosphonates; Teriparatide; Osteoblasts
类别
资金
- Merck
- Proctor and Gamble
- Eli Lilly
- Novartis
- Amgen
Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and fractures are the most frequent adverse effects of this medication. Glucocorticoids have several direct and indirect adverse effects on bone, primarily through reduction in osteoblasts and osteocyte activity, and life span. Recent advances in the pathophysiology and prevention of this complication of therapy provide hope for its amelioration in patients being treated with glucocorticoids. Several effective pharmacologic agents are now available, and guidelines for the prevention and treatment of GIOP have been published. Despite these advances, many patients still do not receive proper prevention or therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据